Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04605666
What this trial is testing

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Nanfang Hospital, Southern Medical University 77
Early research (Phase 1)UnknownNCT04008251
What this trial is testing

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell Lymphoma
Wuhan Sian Medical Technology Co., Ltd 10
Early research (Phase 1)UnknownNCT05978661
What this trial is testing

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Who this might be right for
Light Chain Amyloidosis
Nanjing University School of Medicine 12
Testing effectiveness (Phase 2)Study completedNCT01747486
What this trial is testing

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Who this might be right for
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
University of Pennsylvania 42
Not applicableLooking for participantsNCT07472972
What this trial is testing

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Who this might be right for
LymphomaLymphoid Hematological Malignancies
University of Zurich 50
Early research (Phase 1)Active Not RecruitingNCT06222853
What this trial is testing

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErythematosusCAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine 22
Very early researchLooking for participantsNCT07429461
What this trial is testing

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia
Zhejiang University 16
Testing effectiveness (Phase 2)UnknownNCT02685670
What this trial is testing

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+19 more
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Not applicableLooking for participantsNCT07248163
What this trial is testing

Universal CAR-T Cell Therapy for NHL

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Bioray Laboratories 6
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Not applicableEnrolling By InvitationNCT07517536
What this trial is testing

CHT105 for the Treatment of Refractory Lupus Nephritis

Who this might be right for
Systemic Lupus ErythematosusLupus Nephritis
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 14
Early research (Phase 1)Study completedNCT02631044
What this trial is testing

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Who this might be right for
Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more
Juno Therapeutics, a Subsidiary of Celgene 387
Testing effectiveness (Phase 2)WithdrawnNCT06005649
What this trial is testing

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Juventas Cell Therapy Ltd.
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Early research (Phase 1)Active Not RecruitingNCT04684563
What this trial is testing

HuCART19-IL18 in CD19+ Cancers

Who this might be right for
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
University of Pennsylvania 72
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Testing effectiveness (Phase 2)Study completedNCT02650999
What this trial is testing

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Who this might be right for
CD19+ Diffuse Large B-cell LymphomasFollicular LymphomasMantle Cell Lymphomas
Abramson Cancer Center at Penn Medicine 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07162571
What this trial is testing

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Who this might be right for
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 17
Early research (Phase 1)Temporarily pausedNCT06447987
What this trial is testing

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 24
Early research (Phase 1)UnknownNCT03208556
What this trial is testing

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Peking University 20
Next Page